Which should be the goals of apolipoprotein A1? Analysis of a healthy population in Argentina

Walter Masson, Daniel Siniawski, Patricia Sorroche, Walter Scordo

Abstract


Background

Recent studies have demonstrated that apolipoprotein A1 (ApoA) is a better predictor of cardiovascular risk than HDL-C. However, the definite goals of this new marker have not been clearly defined.

Objective

The objective of this study was to infer the goals of ApoA from a healthy population.

Methods

The distribution of ApoA and HDL-C in 304 blood donors was analyzed according to gender. ApoA goals were assumed using two strategies: 1) a simple linear regression model, and 2) percentile analyses.

Results

In the percentile analyses, ApoA levels of 126 and 147 mg/dL corresponded to recommended goals for HDL-C in men and women, respectively. The linear regression model showed that 40 and 50 mg/dL HDL-C corresponded to 140 and 158 mg/dL ApoA in men and women, respectively.

Conclusion

The findings of this study suggest that previously postulated ApoA goals should be reviewed in both genders.


References


Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.

Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98.

van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.

Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.

Ansell BJ. The two faces of the ‘good’ cholesterol. Cleve Clin J Med 2007;74:697-705.

Walldius G, Jungner I, Holme I, Aastveit AH, Werner Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.

McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33.

Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-92.

Siniawski D, Masson W, Bluro I, Sorroche P, Scordo W, Krauss J, et al. Niveles plasmáticos de apolipoproteínas en una población saludable de la Argentina: implicaciones en prevención cardiovascular. Rev Argent Cardiol 2010;78:123-8.

Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997;43:2364-78.

Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apoliprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998;44:1641-9.

Contois JH, Macnamara JR, Lammi-Keefe CJ, Wilson PW, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immune turbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:507-14.

Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205.

Reiner Z, Catapano AL, De Becker G, Graham I, Taskinen MR, Wiklund O, et al. Guía de la ESC/EAS sobre el manejo de las dislipemias. Rev Esp Cardiol 2011;64:1168:e1-e60.


Full Text

Refbacks

  • There are currently no refbacks.


Licencia Creative Commons
The documents published in this journal are under the licencia Creative Commons Atribución-NoComercial-Compartir-Igual 2.5 Argentina.

Revista argentina de cardiología. ISSN en línea 1850-3748. Argentine journal of cardiology (English ed. Online ISSN 2314-2286) Sociedad Argentina de Cardiología. Azcuénaga 980 (C1115AAD),Ciudad Autónoma de Buenos Aires, República Argentina. Tel. (54 11) 4961-6027/8/9 Fax: 4961-6020 www.sac.org.ar revista@sac.org.ar